Page 32 - Demo

36 PROCEEDINGS OF INTERNATIONAL SCIENTIFIC CONFERENCE ON APPLIED BIOTECHNOLOGY4. Grzelak, E.M.; Choules, M.P.; Gao, W.; Cai, G.; Wan, B.; Wang, Y.; McAlpine, J.B.; Cheng, J.; Jin, Y.; Lee, H.; et al. Strategies in Anti-Mycobacterium Tuberculosis Drug Discovery Based on Phenotypic Screening. J Antibiot 2019, 72, 719%u2013728, doi:10.1038/s41429-019-0205-9.5. Tuberculosis Drugs and Mechanisms of Action | NIAID: National Institute of Allergy and Infectious Diseases Available online: https://www.niaid.nih.gov/diseases-conditions/tbdrugs (accessed on 7 December 2024).6. Collins, L.; Franzblau, S.G. Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compounds against Mycobacterium Tuberculosis and Mycobacterium Avium. Antimicrob Agents Chemother 1997, 41, 1004%u20131009, doi:10.1128/AAC.41.5.1004.7. Gao, W.; Kim, J.-Y.; Anderson, J.R.; Akopian, T.; Hong, S.; Jin, Y.-Y.; Kandror, O.; Kim, J.-W.; Lee, I.-A.; Lee, S.-Y.; et al. The Cyclic Peptide Ecumicin Targeting ClpC1 Is Active against Mycobacterium Tuberculosis In Vivo. Antimicrob Agents Chemother 2015, 59, 880%u2013889, doi:10.1128/AAC.04054-14.8. Hanson, P.I.; Whiteheart, S.W. AAA+ Proteins: Have Engine, Will Work. Nat Rev Mol Cell Biol 2005, 6, 519%u2013529, doi:10.1038/nrm1684.9. Lupas, A.; Flanagan, J.M.; Tamura, T.; Baumeister, W. SelfCompartmentalizing Proteases. Trends in Biochemical Sciences1997, 22, 399%u2013404, doi:10.1016/S0968-0004(97)01117-1.10. Akopian, T.; Kandror, O.; Raju, R.M.; UnniKrishnan, M.; Rubin, E.J.; Goldberg, A.L. The Active ClpP Protease from M. Tuberculosis Is a Complex Composed of a Heptameric ClpP1 and a ClpP2 Ring. The EMBO Journal 2012, 31, 1529%u20131541, doi:10.1038/emboj.2012.5.